Peptron

087010.KQ

178.37 USD

-3.29

-1.81%

Overview

Last close

178.37 usd

Market cap

2.73B usd

52 week high

262.86 usd

52 week low

54.60 usd

Target price

23.65 usd

Valuation

P/E

N/A

Forward P/E

N/A

Price/Sales

1139.4782

Price/Book Value

43.8651

Enterprise Value

4.16B usd

EV/Revenue

1091.7594

EV/EBITDA

-17.5233

Key financials

Revenue TTM

3.93M usd

Gross Profit TTM

3.02M usd

EBITDA TTM

-7.26M usd

Earnings per Share

N/A usd

Dividend

N/A usd

Total assets

124.06M usd

Net debt

17.12M usd

About

Peptron, Inc. engages in the development of peptide-based medicines. The company's technologies include long acting; and SmartDepot, an ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of drug. Its research and development products include Luphere Depot for prostate cancer, endometriosis, uterine fibroids, premenopausal breast cancer, and puberty; SR-Octreotide for the treatment of acromegaly; SR-Exenatide to treat type 2 diabetes; and SR-Exenatide (PT320) for Parkinson's and Alzheimer's disease. Peptron, Inc. was founded in 1997 and is headquartered in Daejeon, South Korea.